fenoldopam has been researched along with 3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asico, LD; Fu, C; Han, Y; He, D; Huang, L; Jose, PA; Li, Z; Ren, H; Shi, W; Wang, X; Yang, C; Yu, C; Zeng, C; Zhou, L | 1 |
1 other study(ies) available for fenoldopam and 3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol
| Article | Year |
|---|---|
Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Aorta; Benzopyrans; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Dopamine Agonists; Dose-Response Relationship, Drug; Fenoldopam; Molecular Chaperones; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Norepinephrine; Oxazines; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2008 |